Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Calvez

Showing results (311-320 of 329) with videos related to

Pageof 33
Sort By:
Antimicrobial Agents and Chemotherapy|November 11, 2009
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patientsAnne-Genevieve Marcelin, Philippe Flandre, Diane Descamps, et al.
Plos One|November 20, 2020
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19Thierry Poynard, Olivier Deckmyn, Marika Rudler, et al.
The Journal of Antimicrobial Chemotherapy|January 18, 2018
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimenCharlotte Charpentier, Isabelle Malet, Elisabeth Andre-Garnier, et al.
International Journal of Antimicrobial Agents|April 9, 2013
A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failureAnne-Geneviève Marcelin, Constance Delaugerre, Céline Beaudoux, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patientsAnne-Geneviève Marcelin, Isabelle Cohen-Codar, Martin S King, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 3, 2019
New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017Marc Wirden, Fabienne De Oliveira, Magali Bouvier-Alias, et al.
The Journal of Antimicrobial Chemotherapy|June 27, 2013
National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011Diane Descamps, Lambert Assoumou, Marie-Laure Chaix, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasmaCathia Soulie, Diane Descamps, Maxime Grudé, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2019
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patientsAnne-Genevieve Marcelin, Maxime Grude, Charlotte Charpentier, et al.
Antimicrobial Agents and Chemotherapy|June 10, 2026
A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approvalCharlotte Charpentier, Thomas Montrouge, Marc Wirden, et al.
Pageof 33

Showing results (311-320 of 329) with videos related to

Sort By:
Pageof 33
Antimicrobial Agents and Chemotherapy|November 11, 2009
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patientsAnne-Genevieve Marcelin, Philippe Flandre, Diane Descamps, et al.
Plos One|November 20, 2020
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19Thierry Poynard, Olivier Deckmyn, Marika Rudler, et al.
The Journal of Antimicrobial Chemotherapy|January 18, 2018
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimenCharlotte Charpentier, Isabelle Malet, Elisabeth Andre-Garnier, et al.
International Journal of Antimicrobial Agents|April 9, 2013
A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failureAnne-Geneviève Marcelin, Constance Delaugerre, Céline Beaudoux, et al.
Antimicrobial Agents and Chemotherapy|April 28, 2005
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patientsAnne-Geneviève Marcelin, Isabelle Cohen-Codar, Martin S King, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 3, 2019
New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017Marc Wirden, Fabienne De Oliveira, Magali Bouvier-Alias, et al.
The Journal of Antimicrobial Chemotherapy|June 27, 2013
National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011Diane Descamps, Lambert Assoumou, Marie-Laure Chaix, et al.
The Journal of Antimicrobial Chemotherapy|October 27, 2014
Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasmaCathia Soulie, Diane Descamps, Maxime Grudé, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2019
Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patientsAnne-Genevieve Marcelin, Maxime Grude, Charlotte Charpentier, et al.
Antimicrobial Agents and Chemotherapy|June 10, 2026
A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approvalCharlotte Charpentier, Thomas Montrouge, Marc Wirden, et al.
Pageof 33